At around ₹53 (NSE, last close ~₹53.1), Suzlon is trading closer to the lower end of its recent 52‑week range of about ₹46–74, and is down ~21% over the last 12 months. (investing.com)

1. Street view and indicative targets (not recommendations)

Several brokerages remain positive on Suzlon with 6–12 month views:

- Morgan Stanley: Overweight with a target of ~₹73. (livemint.com)

- Motilal Oswal: Initiated coverage with ‘Buy’ and a target of ~₹70. (moneycontrol.com)

- ICICI Securities & Motilal (recent ET report): Target around ₹76. (m.economictimes.com)

- Investing.com analyst consensus: ~₹73.8 fair value target, implying ~35–40% potential from current levels. (investing.com)

These are example institutional targets, generally on at least a few quarters’ horizon, not ultra‑short‑term (days/weeks) trading targets.

2. Short‑term trading perspective (example framework only)

From a purely price/technical and recent‑news angle:

- Recent price action & volatility

- Stock is ~30%+ below its 52‑week high and has seen ~18% correction over a 3‑month window in mid‑2025, showing it is high‑beta and sentiment‑sensitive. (samco.in)

- Key zones traders often watch (illustrative levels, not advice):

- Immediate support: ₹46–48 zone (recent 52‑week low/major support). (investing.com)

- Near‑term resistance:

- First band: ~₹60 (round‑number, prior congestion area; some earlier technical commentary treated a breakout above ₹50–51 as bullish toward this zone). (etnownews.com)

- Next band: ₹68–74 (cluster of multiple broker targets and 52‑week high). (moneycontrol.com)

Example (not a recommendation):

- A short‑term trader buying near ₹52 might plan for an upside trading band of ~₹60–68 over a 1–3 month view, with a downside risk back to ~₹46–48 if sentiment turns. That is roughly:

- Upside: +15–30%

- Downside to support: −8–12%

Whether that risk–reward is acceptable depends entirely on your risk appetite, position sizing and ability to tolerate volatility.

3. Fundamental and risk snapshot

Positives (medium‑term supportive):

- Strong position in Indian wind segment; CRISIL highlighted Suzlon’s large market share and improving balance sheet when upgrading its rating to ‘CRISIL A’ with a positive outlook. (upstox.com)

- Q2 FY26 results showed a very sharp jump in profitability (net profit ~₹1,278–1,279 crore vs ~₹200 crore YoY), which underpins many of the bullish brokerage targets. (business-standard.com)

- Structural tailwind from India’s renewable/wind capex cycle, which is the core basis for Motilal, Morgan Stanley and others remaining positive. (moneycontrol.com)

Key risks (especially for short‑term entries):

- Earnings are still lumpy; there have been quarters that disappointed street expectations, triggering sharp corrections. (samco.in)

- Stock has reacted to management churn (e.g., CFO exit) and headline news in the past—moves can be swift on either side. (samco.in)

- Policy, execution and order‑timing risks are inherent in capital‑goods/renewables names.

4. Practical interpretation of “Is it a buy at ₹52?”

- For a short‑term trader: The stock is volatile, and you are buying a high‑beta name close to support but in a sideways‑to‑corrective phase versus its highs. Any trade needs a very clear stop‑loss (for example, somewhere below the ₹46–48 support band) and a pre‑defined exit zone (like ₹60–68), keeping position size small. This is an example framework, not a personalised recommendation.

- For a higher‑risk investor (6–12+ months): Many brokerages still project 30–40% upside from current levels based on earnings visibility and sector tailwinds, but this comes with above‑average drawdown risk and dependence on execution of the order book.

Because I do not know your capital, risk tolerance, holding period, or existing exposure, I cannot say “definitively buy” or “don’t buy” at ₹52. The decision should be based on whether:

1. You are comfortable with meaningful price swings and potential drawdowns.

2. Your horizon is long enough to align with institutional targets (quarters, not days).

3. The position size is small enough not to hurt your overall portfolio if the trade goes wrong.

If you want to proceed, review the latest investor presentations/earnings call transcript and your own risk parameters before taking any action.

If you have any further queries, please connect with us on 022-6290-10141 (Timings : 09.00 AM to 05.00 PM) or you can email us on info@cniinfoxchange.com